Skip to main content

Illumina, Nanosys, Paradigm

Premium

Illumina Revenues Up

Illumina reported increased revenues for the first quarter last week, amid nearly flat net losses.

The San Diego genotyping and oligonucleotide company’s revenues for the quarter totaled $4.3 million, up from $1.3 million for the year-ago quarter. Net losses totaled $9.0 million, up from $8.7 million for the first quarter of 2002. Research and development expenses were $5.7 million, from $7.1 million in Q1 2002.

 

Nanosys GET New Funders in $30M Series B

Nanosys of Palo Alto, Calif., last week announced new investors in the first closing of its $30 million Series B funding. The company’s new investors in an initial closing of funding include CDIB BioScience Ventures, Chiao Tung Bank, China Development Industrial Bank, Harris & Harris, Lux Capital, Quanta Computer, and SAIC Venture Capital Corp.

 

Paradigm Gets $8.4M More in NIEHS Funding

Paradigm Genetics of Research Triangle Park, NC, will receive $8.4 million from the National Institute of Environmental Health Sciences for toxicogenomics studies, in addition to $23.8 million already funded under a five-year contract, the company said last week. The original contract calls for Paradigm researchers to use a gene-expression platform based on technology developed at Agilent Technologies to discern what happens to an organism when an undisclosed variety of toxicants, drugs, and pesticides have been introduced.

Some $2 million will go toward research for the National Toxicology Program.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.